All News
Filter News
Found 253 articles
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Alto Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/23/2022
Alto Neuroscience Inc. today announced Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.
-
Alto Neuroscience Announces Positive Data from Phase 1 Study Evaluating Brain Effects of Novel Drug Combinations
12/14/2022
Alto Neuroscience today announced top-line results from a Phase 1 human brain mechanism study of a series of novel combination drugs targeting the cyclic-AMP pathway, a key driver of cognition, memory, and mood in mental health conditions.
-
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology
12/8/2022
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology.
-
Alto Neuroscience Wins 2022 BioTech Breakthrough and BioSpace’s 2023 Best Places to Work Awards
11/15/2022
Alto Neuroscience today announced it was selected as the 2022 Overall BioPharma Innovation of the Year award winner by BioTech Breakthrough, in addition to being selected as one of BioSpace ’s 2023 Best Places to Work in Biopharma.
-
Alto Neuroscience Announces $35 Million Series B Financing
10/25/2022
Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital.
-
ONWARD Announces Participation at Upcoming Events in October 2022
9/29/2022
ONWARD Medical N.V. announced that management will participate in the following upcoming events in October: Investors’ Day Geneva October 5, 2022 Geneva, Switzerland Dave Marver, CEO, will give a company presentation.
-
Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
9/16/2022
Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit.
-
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
9/15/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present seven abstracts from across its neuroscience portfolio at the 35th annual Psych Congress 2022, being held September 17-20, 2022.
-
BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies' employment growth.
-
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
8/19/2022
Akili, a leading digital medicine company, completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I, a publicly traded special purpose acquisition company.
-
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
6/8/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced that Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.
-
Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.
-
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
6/1/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its neuroscience portfolio at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies (APSS).
-
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
-
Alto Neuroscience CEO, Amit Etkin, M.D., Ph.D., Appointed to NIDA’s National Advisory Council on Drug Abuse (NACDA)
5/12/2022
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., has been appointed to serve as a member of the National Institute on Drug Abuse’s (NIDA) National Advisory Council on Drug Abuse (NACDA).
-
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
5/12/2022
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present seven abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – June 7, 2022, and eight abstracts at the 27th Annual Congress of the European Hematology Association (EHA) from June 9 –12, 2022.
-
Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)
4/25/2022
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participate in the B. Riley Virtual Neuro & Opthalmology Healthcare Conference at 10:00AM ET on April 27, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Dubai on the Brain: NeuroVigil’s Philip Low Assembles Dream Team to Launch Modern Neurotechnology Industry; Expands Conglomerate in Montreal, Canada
3/22/2022
Neurotechnology Powerhouse NeuroVigil announced at the New Technology & Mental Health Conference keynote during Dubai’s World Expo that it has recruited senior captains of industry, government and academia to scale operations leading up to the launch of its newest non-invasive iBrain™ brain monitor, designated by the New York Times as “an innovation which will change your tomorrow”.